Trials / Withdrawn
WithdrawnNCT03070691
Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)
A Randomized, Double-blind, Vehicle-controlled, Multicenter Trial of Topically Administered LDE225 Cream (0.75% Bid) to Evaluate Clearance of Basal Cell Carcinoma in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome
- Status
- Withdrawn
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This 22 week study will assess the efficacy, safety, and tolerability of LDE225 versus vehicle when applied topically to basal cell carcinoma (BCC) in patients with NBCCS. Patients will treat multiple BCCs for up to 12 weeks. Treatment success is defined as complete clinical clearance and complete histological clearance in BCCs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LDE225B | Cream, 2x daily |
| DRUG | Vehicle | cream, 2x daily |
Timeline
- First posted
- 2017-03-03
- Last updated
- 2017-05-05
Locations
35 sites across 10 countries: Belgium, Canada, Czechia, Finland, Germany, Greece, Italy, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT03070691. Inclusion in this directory is not an endorsement.